Filspari Granted Accelerated Approval to Reduce Proteinuria in IgA Nephropathy
Sparsentan is an endothelin and angiotensin II receptor antagonist.
Diagnosis & Disease Information
Novel Oral Anticoagulant Fast Tracked for Patients With ESRD and Atrial Fibrillation
Tecarfarin is a novel oral vitamin K antagonist with a similar mechanism of action to warfarin, though it is metabolized differently.
Oxlumo Indication Expanded to Include Patients With Advanced PH1
The approval was based on data from the phase 3 ILLUMINATE-C study that included 21 dialysis-independent and -dependent patients with PH1.
Therapeutic Peptide Granted Orphan Drug Status for Hepatorenal Syndrome
The Company is currently evaluating OCE-205 in a phase 2 trial in adults who have developed hepatorenal syndrome with acute kidney injury.
FDA Clears Bodyport Cardiac Scale to Monitor Heart Function, Fluid Status
The Bodyport Cardiac Scale is designed to detect signals through an individual’s feet to noninvasively measure a broad spectrum of hemodynamic biomarkers for heart function and fluid status.
Terlipressin Decision Delayed Due to Manufacturing Facility Change
In the CRL, the FDA stated that a satisfactory inspection is required before the NDA can be approved.
Researchers Identify Abnormal Plasma Proteins From Patients With Gout Using HPLC-MS/MS
Researchers detected differential proteins in the plasma of patients with gout, patients with gout with kidney damage, and individuals without gout.
Chronic Kidney Disease: What Your Patients Need to Know
Although chronic kidney disease (CKD) is among the more common kidney ailments, patients may not be well-versed in its symptoms or complications. What should patients know about CKD, and how should healthcare providers be educating them?
Update for SGLT2 Inhibitors: Temporary Discontinuation Prior to Surgery Recommended
The FDA has approved safety labeling changes for sodium glucose co-transporter-2 (SGLT2) inhibitors. These include canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.
Empagliflozin Fast-Tracked for Chronic Kidney Disease Treatment
The FDA has granted Fast Track designation for empagliflozin (Jardiance; Boehringer Ingelheim and Lilly) to reduce the risk of kidney disease progression and cardiovascular (CV) death in adults with chronic kidney disease.
- Loading...
Loading...
Next post in Chronic Kidney Disease (CKD)
Loading... 
Loading...